Graham Samuel-Gibbon

Graham is Head of our Tax and Incentives team in the UK. He is an international tax specialist who advises domestic and multinational clients on a wide range of transactional and advisory tax matters. Graham regularly works with FTSE 100 and Future Global 100 companies.

He guides clients through stock and asset/business acquisitions and disposals, crossborder tax structuring, UK inbound and outbound investment, joint ventures and reorganisations.

He also advises on tax issues relating to the development, ownership and exploitation of intellectual property rights, with a particular focus on the life science and technology sectors.

Show full CV Hide full CV

Career

Since 2017	Partner, Taylor Wessing
2014 - 2017	Director, EY
2007 - 2014	Senior Associate, Latham & Watkins

2005 - 2007

Associate, Hogan Lovells

More Less

Education

2001	Master's Degree, Jurisprudence II, University of Oxford, UK
2000	French Law, Université Panthéon Assas, Paris II, France

Additional languages

English

French

Expertise

Services and Groups Tax Corporate tax/M&A tax structuring/Taxation on transactions Media & IP taxation Banking & finance taxation Tax disputes Tax, tax risk and tax planning Venture capital taxation

Sectors Technology, media & communications Consumer & retail Life sciences & healthcare Manufacturing & industrials Fintech Cryptoassets, blockchain and distributed ledger technology

Experience

EQT on £1bn residential real estate joint venture.	Advised global investor EQT on a £1bn residential real estate joint venture, set to bring 3000 new rental homes to Greater London. The billion-sterling investment portfolio is being launched with residential property developer Sigma Capital. It is the first UK investment for EQT Real Estate, a division of global investor EQT Partners.
Glenmark Pharma on the sale of its portfolio of CNS products in Poland to Neuraxpharm	Glenmark Pharma on its divestment of its CNS business in Poland including its portfolio of generics and branded generics products and the transfer of its commercial team in Poland to private equity backed Neuraxpharm, a specialty pharmaceutical company focused on the treatment of CNS disorders.
Babylon Health continues to invest in digital healthcare with largest European and US fundraising	Babylon Health, a UK-based digital health subscription provider, on its USD550m fundraising to support expansion into the US and Asia. This is the largest ever fundraising in the European or US digital health sector and values Babylon at over USD2bn. Investors included PIF, ERGO Fund, Kinnevik and Vostok New Ventures.

Secret Escapes on the acquisition of TravelBird and Pigsback.com	Secret Escapes on the acquisition of Dutch based TravelBird, the online luxury and experience company, and Pigsback.com, the market leading marketplace in Ireland for online hospitality offers.
World's longest standing cryptocurrency exchange, Bitstamp, sells 80% stake to NXMH	We advised on the 80% sale of Bitstamp to Brussels-based investment firm, NXMH. Founded in the UK in 2011, Bitstamp is the world's longest standing cryptocurrency exchange and the EU's largest by volume, with more than three million registered customers.
Advising EQT Real Estate on £1billion joint venture for London	We have advised global investor EQT on a £1 billion residential real estate joint venture, set to bring 3000 new rental homes to Greater London. The billion-sterling investment portfolio of high-quality build-to-rent residential homes is being launched with residential property developer Sigma Capital. It is the first UK investment for EQT Real Estate, a division of global investor EQT Partners.